Biotech firm Asylia Therapeutics raises $14.5M, names founding CEO
Houston-based biotechnology firm Asylia Therapeutics Inc. raised $14.5 million to advance its clinical trials for cancer drugs.
The Series A round was led by Houston-based Sporos Bioventures, Asylia announced May 25. The company will use proceeds to bring Asylia's assets to first-in-human clinical trials for oncology. Asylia could potentially generate proof-of-concept signals for its clinical assets in treating autoimmune diseases like lupus, the firm said.
"While cancer research has come a significant…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Chris Mathews Source Type: news
More News: Autoimmune Disease | Biotechnology | Cancer | Cancer & Oncology | Clinical Trials | Health Management | Lupus